Mass Screening Ovarian Cancer Diagnostic Would Boost Survival Rates, UK

HealthLinx Limited (ASX:HTX), has reached an agreement with The University of Liverpool (UK) to in-license additional patented biomarker technology and antibodies that has shown efficacy in detecting grade I & II ovarian cancer. HealthLinx and The University of Liverpool (UK) have been jointly developing this technology over the past twelve months which has potential to be the world’s first commercially available, multi-marker early stage ovarian cancer diagnostic. [click link for full article]

More: continued here

Filed under: Cervical Cancer on December 2nd, 2007